TGTsumugi Gebo

Tsumugi Gebo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tsumugi Gebo has a total of 37 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Supplementary Figures S1-S22 from The Landscape of Prostate Tumor Methylation

    by Jaron Arbet, Takafumi N. Yamaguchi, Yu-Jia Shiah, Rupert Hugh-White, Adriana Wiggins, Jieun Oh, Nicole Zeltser, Tsumugi Gebo, Adrien Foucal, Robert Lesurf, et al.

    Supplementary Figure 1 shows sample size and available data types by cohort, pre-treatment clinical feature distributions, subtype-selection results, and methylation profiles of subtype-defining CpGs Supplementary Figure 2 illustrates methylation profiles stratified by cohort, tissue type and methylation subtype Supplementary Figure 3 shows tumour purity distributions, clinical feature distributions, and cohort-specific Kaplan-Meier analyses of time to biochemical recurrence by methylation subtype Supplementary Figure 4 presents CIMP association patterns across methylation subtypes and key clinico-molecular features Supplementary Figure 5 illustrates subtype-defining CpGs by tissue and tumour type and presents sensitivity analyses of the PTEN methylation-CNA interaction Supplementary Figure 6 shows distributions of methylation-CNA correlations stratified by tumour type and the presence or absence of 14 driver mutation events Supplementary Figure 7 displays multi-omic correlations between methylation, CNA, and RNA in localized and metastatic samples Supplementary Figure 8 illustrates mutual information across multi-omic data types in localized and metastatic samples. Supplementary Figure 9 highlights genomic, transcriptomic, and clinical features of genes with high variation in methylation Supplementary Figure 10 presents genome-wide CNA profiles by methylation subtype and cohort Supplementary Figure 11 displays chromosome-level CNA profiles by methylation subtype and cohort Supplementary Figure 12 shows distributions of categorical driver mutations stratified by methylation subtype. Supplementary Figure 13 shows RNA expression differences across methylation subtypes and associations between hypoxia scores and DNA methylation Supplementary Figure 14 presents associations between driver events and DNA methylation, including CpG-level methylation distributions, genomic annotation of driver-associated CpGs, mRNA abundance patterns, and TP53-related methylation effects Supplementary Figure 15 compares driver mutation patterns between localized and metastatic prostate cancers Supplementary Figure 16 shows test-dataset model performance after feature selection for methylation-based prediction of clinical and molecular features Supplementary Figure 17 compares training- and test-dataset performance across all feature-selection settings and model types Supplementary Figure 18 shows final model performance on the test dataset for predicted clinical and molecular features Supplementary Figure 19 displays final model performance stratified by cohort Supplementary Figure 20 illustrates the PrCaMethy R package workflow and overlap of predictors across methylation-based prediction models Supplementary Figure 21 summarizes multi-omic model construction, feature selection, and performance for predicting time to biochemical recurrence Supplementary Figure 22 shows the association between epigenetic and genetic subtypes in prostate cancer, relating the four methylation-subtypes (MS-1 through MS-4) from this study to the seven integrated molecular subtypes (IMS-1 through IMS-7) from Yamaguchi et al. Cancer Discovery 2025 (PMID: 39945744)

  • Open Access

    Supplementary Information 1 from The Landscape of Prostate Tumor Methylation

    by Jaron Arbet, Takafumi N. Yamaguchi, Yu-Jia Shiah, Rupert Hugh-White, Adriana Wiggins, Jieun Oh, Nicole Zeltser, Tsumugi Gebo, Adrien Foucal, Robert Lesurf, et al.

    Analysis of associations between tumour methylation and self-identified race, ancestry and tumour purity. Six extended figures outline these analyses, demonstrating associations with subtype classification and univariable clinico-molecular features.

  • Open Access

    Supplementary Table 3 from The Landscape of Prostate Tumor Methylation

    by Jaron Arbet, Takafumi N. Yamaguchi, Yu-Jia Shiah, Rupert Hugh-White, Adriana Wiggins, Jieun Oh, Nicole Zeltser, Tsumugi Gebo, Adrien Foucal, Robert Lesurf, et al.

    Supplementary Table 3 summarizes the inventory of methylation datasets used in this study, including data type, profiling technology, and data source

  • Open Access

    Supplementary Table 4 from The Landscape of Prostate Tumor Methylation

    by Jaron Arbet, Takafumi N. Yamaguchi, Yu-Jia Shiah, Rupert Hugh-White, Adriana Wiggins, Jieun Oh, Nicole Zeltser, Tsumugi Gebo, Adrien Foucal, Robert Lesurf, et al.

    Supplementary Table 4 provides methylation subtype assignments and CIMP scores for all samples, including unadjusted CIMP score and CIMP score adjusted for profiling technology and cohort.

  • Open Access

    Supplementary Table 1 from The Landscape of Prostate Tumor Methylation

    by Jaron Arbet, Takafumi N. Yamaguchi, Yu-Jia Shiah, Rupert Hugh-White, Adriana Wiggins, Jieun Oh, Nicole Zeltser, Tsumugi Gebo, Adrien Foucal, Robert Lesurf, et al.

    Supplementary Table 1 summarizes clinical and demographic characteristics for prostate tumour samples overall and stratified by methylation subtype

  • Open Access

    Supplementary Table 2 from The Landscape of Prostate Tumor Methylation

    by Jaron Arbet, Takafumi N. Yamaguchi, Yu-Jia Shiah, Rupert Hugh-White, Adriana Wiggins, Jieun Oh, Nicole Zeltser, Tsumugi Gebo, Adrien Foucal, Robert Lesurf, et al.

    Supplementary Table 2 summarizes demographic characteristics of normal prostate samples overall and stratified by methylation subtype

  • Open Access

    Supplementary Table 7 from The Landscape of Prostate Tumor Methylation

    by Jaron Arbet, Takafumi N. Yamaguchi, Yu-Jia Shiah, Rupert Hugh-White, Adriana Wiggins, Jieun Oh, Nicole Zeltser, Tsumugi Gebo, Adrien Foucal, Robert Lesurf, et al.

    Supplementary Table 7 shows sample-level clinico-molecular outcome annotations used to train and test all models, provided in the clinico-molecular_annotations sheet. The Top100_CpGs sheet lists the 100 CpGs most strongly associated with each driver mutation or mutation burden (rows = CpGs; columns = driver mutations or mutation burden), corresponding to the data shown in Supplementary Figure 14g. Variable importance scores for the gene-level methylation predictors used in each predictive model (separate sheet per model), scaled from 0 (least important) to 100 (most important)

  • Open Access

    Supplementary Table 5 from The Landscape of Prostate Tumor Methylation

    by Jaron Arbet, Takafumi N. Yamaguchi, Yu-Jia Shiah, Rupert Hugh-White, Adriana Wiggins, Jieun Oh, Nicole Zeltser, Tsumugi Gebo, Adrien Foucal, Robert Lesurf, et al.

    Supplementary Table 5 lists 91 established prostate cancer driver genes compiled from Fraser et al., Rheinbay et al., Bailey et al., and Armenia et al.,. Gene coordinates are reported in GRCh38.

  • Open Access

    Supplementary Table 6 from The Landscape of Prostate Tumor Methylation

    by Jaron Arbet, Takafumi N. Yamaguchi, Yu-Jia Shiah, Rupert Hugh-White, Adriana Wiggins, Jieun Oh, Nicole Zeltser, Tsumugi Gebo, Adrien Foucal, Robert Lesurf, et al.

    Supplementary Table 6 lists (i) 3,516 mRNA transcripts that differ significantly between methylation subtypes with large effect sizes, and (ii) 1,046 genes whose promoter CpG island methylation is significantly correlated with hypoxia score.

  • Open Access

    The Landscape of Prostate Tumor Methylation

    by Jaron Arbet, Takafumi N. Yamaguchi, Yu-Jia Shiah, Rupert Hugh-White, Adriana Wiggins, Jieun Oh, Nicole Zeltser, Tsumugi Gebo, Adrien Foucal, Robert Lesurf, et al.

    Prostate cancer is characterized by profound clinical and molecular heterogeneity. Although its genomic heterogeneity is well characterized, its epigenomic heterogeneity remains less understood. We therefore created a compendium of 3,001 multiancestry prostate methylomes spanning normal tissue through localized disease of all grades to polymetastatic disease. A subset of 884 samples had multiomic DNA and/or RNA characterization. We identify four epigenomic subtypes that risk-stratify patients and reflect distinct evolutionary trajectories. We demonstrate extensive regulatory interplay between DNA copy number and methylation, with transcriptional consequences that vary across genes and disease stages. We define epigenetic dysregulation signatures for 15 important clinicomolecular features, creating predictive models for each. For example, we identify specific epigenetic features that predict patient outcome and are synergistic with clinical prognostic features. These results define a complex interplay between tumor genetics and epigenetics that converges to modify gene expression programs and clinical presentation, in part through modulation of epigenetic aging. Significance: We define the largest prostate cancer methylome resource to date, revealing four epigenomic subtypes that stratify cancers by their genetics, evolution, and clinical phenotypes. These data demonstrate that genome–epigenome interactions are stage-dependent, positioning DNA methylation as a central, clinically informative driver of prostate cancer heterogeneity.